Perioperative chemotherapy versus primary surgery for locoregionally advanced resectable adenocarcinoma of the stomach, gastroesophageal junction and lower esophagus
References
Additional references
Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. Journal of the National Cancer Institute 1993;85(22):1839‐44.
Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World Journal of Surgery 1995;19(2):216‐20.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088‐101.
Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago‐gastric junction and gastric adenocarcinoma‐‐individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology 2009;20(5):885‐91.
DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Annals of Surgical Oncology 2006;13(1):12‐30.
Egger M, Davey SG, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.
Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Practice & Research. Clinical Gastroenterology 2006;20(4):633‐49.
Gallo A, Cha C. Updates on esophageal and gastric cancers. World Journal of Gastroenterology 2006;12(20):3237‐42.
Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Annals of Surgery 2001;234(4):520‐30.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Vol. 5.0.0 [updated February 2008], The Cochrane Collaboration, 2008. [www.cochrane‐handbook.org]
Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Seminars in Oncology 1996;23(3):379‐89.
Kikuchi S, Sakakibara Y, Sakuramoto S, Kobayashi N, Shimao H, Mieno H, et al. Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. Anticancer Research 2001;21(5):3589‐93.
Marsman WA, Tytgat GN, Ten Kate FJ, van Lanschot JJ. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. Journal of Surgical Oncology 2005;92(3):160‐8.
Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, et al. Neoadjuvant chemotherapy with cisplatin, 5‐FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6(3):159‐67.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE‐4. Survival of cancer patients diagnosed in 1995‐1999. Results and commentary. European Journal of Cancer 2009;45(6):931‐91.
Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten‐year results of the German Gastric Cancer Study. Annals of Surgery 1998;228(4):449‐61.
Sobin LH, Wittekind C, Sobin LH, Wittekind C. In: Sobin LH, Wittekind C editor(s). TNM Classification of Malignant Tumours (UICC). New York: Wiley‐Liss, 2002.
Wu AW, Xu GW, Wang HY, Ji JF, Tang JL. WITHDRAWN: Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005047.pub3]
